 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--- NBTX ASCO--Regulatory News: NANOBIOTIX Euronext : NANO NASDAQ: NBTX the Company, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the upcoming presentation of updated results from the Companys priority development pathways in head and neck cancer head and neck squamous cell carcinoma; HNSCC and in immunotherapy for advanced cancers at the 2021 